Posts

Posted on

Steel Dynamics Announces Third Quarter 2026 Cash Dividend

PR Newswire

FORT WAYNE, Ind., Aug. 14, 2026 /PRNewswire/ — Steel Dynamics, Inc. (NASDAQ/GS: STLD) today announced that the company’s board of directors declared a third quarter cash dividend of $0.53 per common share. The dividend is payable to shareholders of record at the close of business on September 30, 2026, and is payable on or about October 9, 2026.

Steel Dynamics

About Steel Dynamics, Inc.
Steel Dynamics is a leading industrial metals solutions company, with facilities located throughout the United States, and in Mexico. The company operates using a circular manufacturing model, producing lower-carbon-emission, quality products with recycled scrap as the primary input. Steel Dynamics is one of the largest domestic steel producers and metal recyclers in North America, combined with a meaningful downstream steel fabrication platform. The company has also recently added aluminum operations, further diversifying its product offerings to supply aluminum flat rolled products with higher recycled content to the countercyclical sustainable beverage can industry, in addition to the automotive and industrial sectors. Steel Dynamics is committed to operating with the highest integrity and to being the safest, most efficient producer of high-quality, broadly diversified, value-added metal products.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/steel-dynamics-announces-third-quarter-2026-cash-dividend-302851946.html

SOURCE Steel Dynamics, Inc.

Posted on

Kaplan Fox Advises PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors to Act Before the Lead Plaintiff Deadline on September 22, 2026

NEW YORK, Aug. 14, 2026 (GLOBE NEWSWIRE) — Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation (“PROCEPT” or the “Company”) (NASDAQ: PRCT) on behalf of all purchasers of PROCEPT common stock between February 28, 2024 and February 25, 2026 (the “Class Period”).

CLICK HERE TO JOIN THE CASE

If you are an investor in PROCEPT and have suffered losses, you may

CLICK HERE

to contact us. You may also contact Kaplan Fox by emailing

[email protected]

or by calling (646) 315-9003.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than September 22, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

The complaint alleges that contrary to defendants’ Class Period assurances that the “differential” between handpiece unit sales and procedures had “remained relatively consistent,” PROCEPT’s discount program had caused handpiece orders to materially exceed procedures in every quarter during the Class Period. According to the complaint, these undisclosed sales tactics artificially inflated PROCEPT’s reported U.S. handpiece unit sales and revenues by pulling forward demand at the expense of future periods.

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation’s premier plaintiffs’ securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this Notice, your rights, or your interests, please contact:

CONTACT:

Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
[email protected]

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
[email protected]

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.



Posted on

HDB INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of HDFC Bank Limited Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm

ATLANTA, Aug. 14, 2026 (GLOBE NEWSWIRE) — A shareholder class action lawsuit has been filed against HDFC Bank Limited (“HDFC”) (NYSE: HDB). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (1) HDFC camouflaged payments as marketing spend to pay higher interest to a state firm in order to induce deposits; (2) these activities were approved by senior management; (3) these activities likely violated regulations HDFC’s own policies, including those that prohibit payments that could constitute improper inducement; and (4) as a result of the foregoing, HDFC’s interest income and operating expenses were overstated.

If you purchased HDFC shares between July 17, 2023 and May 26, 2026, and experienced a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/hdfc-bank/ for more information. 

The deadline to ask the court to be appointed lead plaintiff in the case is October 12, 2026.

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.  

CONTACT:
Corey D. Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]



Posted on

Kaplan Fox Advises EquipmentShare.Com Inc (NASDAQ: EQPT) Investors to Act Before the Lead Plaintiff Deadline on September 21, 2026

NEW YORK, Aug. 14, 2026 (GLOBE NEWSWIRE) — Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against EquipmentShare.Com Inc (“EquipmentShare” or the “Company”) (NASDAQ: EQPT) on behalf of investors who purchased or otherwise acquired EquipmentShare common stock pursuant and/or traceable to the Company’s initial public offering on or around January 23, 2026 (the “IPO”), or between January 23, 2026 and June 23, 2026 (the “Class Period”).

CLICK HERE TO JOIN THE CASE

If you are an investor in EquipmentShare and have suffered losses, you may

CLICK HERE

to contact us. You may also contact Kaplan Fox by emailing

[email protected]

or by calling (646) 315-9003.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than September 21, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

According to the complaint, in the IPO, the Company sold 30.5 million shares of Class A common stock at a price of $24.50 per share. Then, on June 24, 2026, according to the complaint, “Umibōzu Research, a stock market focused media outlet, published a report alleging, among other things, that ‘undisclosed related party transactions . . . have netted’ entities affiliated with EquipmentShare founders ‘at least $77 million, with the true figure potentially running substantially higher.’” According to the complaint, on this news EquipmentShare’s stock price fell $1.58, or 6.62%, to close at $22.30 on June 24, 2026, and declined $2.61, or 11.7%, the next trading day to close at $19.69 per share on June 25, 2026.

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation’s premier plaintiffs’ securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this Notice, your rights, or your interests, please contact:

CONTACT:

Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
[email protected]

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
[email protected]

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

https://www.kaplanfox.com/case/equipmentshare-com-inc-class-action-alert-learn-more-now/



Posted on

Kaplan Fox Reminds Investors of a Securities Class Action Against Cogent Communications Holdings, Inc. (NASDAQ: CCOI) – Deadline is September 21, 2026

NEW YORK, Aug. 14, 2026 (GLOBE NEWSWIRE) — Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Cogent Communications Holdings, Inc. (“Cogent” or the “Company”) (NASDAQ: CCOI) on behalf of investors that purchased or otherwise acquired Cogent securities between February 29, 2024 and May 1, 2026 (the “Class Period”).

CLICK HERE TO JOIN THE CASE

If you are an investor in Cogent and have suffered losses, you may

CLICK HERE

to contact us. You may also contact Kaplan Fox by emailing

[email protected]

or by calling (646) 315-9003.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than September 21, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

According to the complaint, throughout the Class Period, “defendants represented that demand for optical wavelengths in Cogent’s newly acquired wireline business was exceptionally strong and rapidly growing.” However, according to the complaint and unknown to investors, “the order backlog that defendants routinely publicized during the Class Period was, by and large, illusory – a fact later confirmed when most of the purported backlog never turned into paying customers even after the Company’s network had been fully repurposed.”

Further, according to the complaint, on May 4, 2026 the CEO and Chairman of the Board David Schaeffer conceded “[o]n wavelength installs, we have seen a variety of customers pushing out their acceptance of wavelengths.” Following this the news, the price of Cogent common stock fell $6.79 per share, or 29% to close at $16.37 per share on May 4, 2026.

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation’s premier plaintiffs’ securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this Notice, your rights, or your interests, please contact:

CONTACT:

Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
[email protected]

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
[email protected]

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.



Posted on

bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

SAN ANTONIO–(BUSINESS WIRE)–bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has closed its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of pre-funded warrants to purchase an aggregate of 8,462,027 shares of common stock. The combined effective offering price for each pre-funded warrant and accompanying two warrants to be issued is $0.4657. The pre-funded warrants will have an exercise price of $0.007 per share of common stock, and the warrants will have an initial exercise price of $0.4727 per share, will be exercisable following stockholder approval, and will expire five years from the date of issuance.

The gross proceeds to the Company from the offering are estimated to be approximately $4.0 million before deducting the placement agent’s fees and other estimated offering expenses.

WallachBeth Capital LLC acted as the sole placement agent in connection with the offering.

The offer and sale of the foregoing securities are being made in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder, and the securities have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company will provide customary registration rights for the shares of common stock underlying the warrants, subject to the terms of the definitive transaction documents.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be made by means of a prospectus.

About bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. LDTs are overseen under the Clinical Laboratory Improvement Amendments (CLIA), which are administered by the Centers for Medicare & Medicaid Services. For more information, visit www.bioaffinitytech.com.

Forward-Looking Statement

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to close the offering when anticipated, and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

bioAffinity Technologies

Julie Anne Overton

Director of Communications

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Biotechnology Health Oncology

MEDIA:

Logo
Logo
Posted on

Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders 

Completed a concurrent PIPE financing raising $132 million in gross proceeds

REDWOOD CITY, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported results for the fiscal quarter ended June 30, 2026, and provided a corporate update.

“We are excited to unite Jasper Therapeutics and Kira Pharmaceuticals to advance our shared mission of developing a differentiated portfolio of innovative therapies for patients with significant immune-mediated diseases. Supported by our recent $132 million financing led by leading life sciences investors, we believe that we have sufficient capital to fund planned operations through the second half of 2028.  We plan to advance development of our lead asset KP-104, a novel dual inhibitor of the complement cascade, in multiple indications, progress briquilimab towards a potential BLA, and to commence first in human studies for KP-701,” said Jeet Mahal, President and Chief Executive Officer of Jasper. “The combined company now has access to significant resources in the United States and China, which we believe will allow us to rapidly advance our portfolio across multiple diseases of unmet need.”

Corporate Updates for Second Quarter 2026 and Recent Weeks

  • On July 16, 2026, Jasper completed the acquisition of Kira Pharmaceuticals (“Kira”), a former Cayman limited company that was engaged in the design of complement therapies to treat immune-mediated diseases, in an all-stock transaction.
  • Concurrently with the acquisition, Jasper entered into a securities purchase agreement for the sale of non-voting convertible preferred stock (the “Preferred Stock”) in a private placement co-led by Affinity Asset Advisors, LLC and Ikarian Capital LLC with participation from other leading life science investors. The private placement resulted in total gross proceeds of approximately $132 million.
  • The combined company is focused on advancing its consolidated pipeline of potential best-in-class innovative therapies for immunologically-driven disorders, including:
    • KP-104 (Vensobafusp alfa), a Phase 2/3 ready, potentially best-in-disease, bifunctional biologic targeting both the alternative and terminal pathways within the complement cascade  for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and high unmet need nephrology disorders. KP-104 is currently being evaluated in a Phase 2 basket trial in rare renal indications and interim data from Stage 1 of the trial is expected in the fourth quarter of 2026. Based on previous, positive results in treatment-naïve PNH, the combined company is also planning for an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and plans to announce next steps for development in PNH in the first half of 2027;
    • Briquilimab, a late-stage, potentially best-in-class anti-KIT antibody with broad therapeutic utility across multiple transplant and immunologic indications. Based on positive, long-term data generated in SCID, the combined company is progressing its efforts towards a pre-BLA meeting with the FDA and expects to announce next steps in the first quarter of 2027; and
    • KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The combined company expects to file a clinical trial application (CTA) and/or an investigational new drug (IND) for Phase 1 evaluation in the first quarter of 2027.

Second Quarter Fiscal 2026 Financial Results

  • Cash and cash equivalents as of June 30, 2026, totaled $7.3 million.
  • Research and development expense for the three months ended June 30, 2026, was $5.1 million.
  • General and administrative expense for the three months ended June 30, 2026, was $4.1 million.
  • Jasper reported a net loss of $2.8 million, or basic and diluted net loss per share attributable to common stockholders of $0.10 for the three months ended June 30, 2026.

About Jasper

The combined company is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. The combined company is advancing a pipeline of medicines including KP-104, briquilimab, and KP-701. KP-104 is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditioning agent for stem cell transplant and mast cell mediated diseases such as chronic urticarias and allergic asthma. KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders currently advancing to the clinic.

Forward-Looking Statements

Certain statements contained in this press release are or may be considered “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as “estimate,” “expect,” “intend,” “believe,” “plan,” “anticipate,” “potential,” “projected” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or condition. Jasper cautions that these statements are based upon the current beliefs and expectations of Jasper’s management and are subject to significant risks, uncertainties and assumptions, including, without limitation, risks related to the market price of Jasper’s common stock relative to the value suggested by the exchange ratio in connection with the merger; unexpected costs, charges or expenses resulting from the merger; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the merger; the uncertainties associated with the Combined Company’s product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment and completion of clinical trials; risks related to the inability of the Combined Company to obtain sufficient additional capital to continue to advance product candidates and its preclinical programs; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; risks associated with the possible failure to realize certain anticipated benefits of the merger, including with respect to future financial and operating results; risks related to the integration of Kira and realization of anticipated benefits from the combination; the possibility that holders of CVRs may never receive any proceeds; risks related to the possibility that Jasper’s shareholders may not approve the conversion of the Preferred Stock and the consequences if such approval is not obtained, and such additional risks and uncertainties contained in the “Risk Factors” section of Jasper’s Annual Reports on Form 10-K for the year ended December 31, 2025, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that Jasper has subsequently filed or may subsequently file with the SEC. Statements regarding future actions, future performance and/or future results including, without limitation, those relating to the timing for completion, and results of, scheduled or additional clinical trials and the FDA’s or other regulatory review and/or approval and commercial launch and sales results (if any) of the Combined Company’s formulations and product candidates and regulatory filings related to the same, financial projections and targets, including, without limitation, cash runway, operating plans, future capital requirements and the sufficiency of existing cash resources, business strategy, plans and objectives for future operations, statements regarding the Combined Company and its operations and prospects, may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. There is no obligation to update publicly or revise any forward-looking statements for any reason after the date of this press release or to conform these statements to actual results or to changes in the Combined Company’s expectations, whether as a result of new information, future events, inaccuracies that become apparent after the date hereof or otherwise, except as may be required under applicable securities laws.

Contacts:

Alex Gray (investors)
Jasper Therapeutics
650-549-1454 
[email protected]

Argot Partners (investors and media)
[email protected] 

  JASPER THERAPEUTICS, INC.
  CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
 
(in thousands, except share and per share data)
 
(unaudited)
                 
                 
    Three Months Ended June 30, 2026   Six Months Ended June 30,
    2026
   2025
   2026
   2025
  Operating expenses              
  Research and development(1) $ 5,135     $ 21,196     $ 10,949     $ 37,353  
  General and administrative(1)   4,072       5,880       9,210       11,525  
  Total operating expenses   9,207       27,076       20,159       48,878  
  Loss from operations   (9,207 )     (27,076 )     (20,159 )     (48,878 )
  Interest income   82       437       246       1,061  
  Change in fair value of warrant liability   3,980       —       13,620       —  
  Other income (expense), net   2,385       (84 )     2,359       (147 )
  Total other income, net   6,447       353       16,225       914  
  Net loss and comprehensive loss $ (2,760 )   $ (26,723 )   $ (3,934 )   $ (47,964 )
  Net loss per share attributable to common stockholders, basic and diluted $ (0.10 )   $ (1.74 )   $ (0.14 )   $ (3.16 )
  Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted   28,696,937       15,333,962       28,684,447       15,178,904  
                 
                 
  (1) Amounts include non-cash stock based compensation expense as follows (in thousands):        
                 
    Three Months Ended June 30, 2026   Six Months Ended June 30,
    2026
   2025
   2026
   2025
                 
  Research and development $ 185     $ 543     $ 406     $ 1,114  
  General and administrative   579       1,274       781       2,514  
  Total $ 764     $ 1,817     $ 1,187     $ 3,628  
                 

  JASPER THERAPEUTICS, INC.
  CONDENSED CONSOLIDATED BALANCE SHEETS
 
(in thousands)
 
(unaudited)
         
    June 30,   December 31,
  Assets 2026
   2025
  Current assets:      
  Cash and cash equivalents $                       7,314     $                     28,692  
  Restricted cash, current                              417        –   
  Prepaid expenses and other current assets   3,840       5,953  
  Total current assets   11,571       34,645  
  Property and equipment, net   60       102  
  Operating lease right-of-use assets   128       502  
  Restricted cash, non-current   –       417  
  Other non-current assets                                43                                  113  
  Total assets $                     11,802     $                     35,779  
         
  Liabilities and Stockholders’ Equity
  		     
  Current liabilities:      
  Accounts payable $                       2,778     $                       6,220  
  Current portion of operating lease liabilities     270         1,235  
  Accrued expenses and other current liabilities   4,797       5,745  
  Total current liabilities   7,845       13,200  
  Warrant liability     2,544         16,164  
  Other non-current liabilities   –         2,264  
  Total liabilities   10,389       31,628  
         
  Stockholders’ equity:      
  Preferred stock     —         —  
  Common stock     3         3  
  Additional paid-in capital     322,014         320,818  
  Accumulated deficit     (320,604 )       (316,670 )
  Total stockholders’ equity     1,413         4,151  
  Total liabilities and stockholders’ equity $                     11,802     $                     35,779  



Posted on

Nexstar’s Local TV Stations Receive Two National Edward R. Murrow Awards for Outstanding Journalism and Exceptionally Produced Content

Nexstar’s Local TV Stations Receive Two National Edward R. Murrow Awards for Outstanding Journalism and Exceptionally Produced Content

KXAN-TV in Austin, TX, Recognized for “Digital”

WHO 13 in Des Moines, IA, Wins Award for “Hard News”

IRVING, Texas–(BUSINESS WIRE)–
Nexstar Media Group, Inc. (NASDAQ: NXST), today announced that KXAN-TV, the company’s television station in Austin, Texas (DMA #32), and WHO 13 in Des Moines, Iowa (DMA #67), have each earned a national Edward R. Murrow Award from the Radio Television Digital News Association (RTDNA). KXAN-TV was recognized in the “Digital” category and WHO 13 for “Hard News.”

Large Market Television: Digital – KXAN’s winning entry was a collection of investigative projects that combined reporting with digital storytelling, video, and other multimedia elements to hold the powerful accountable and give viewers a deeper understanding of important issues across Texas. The projects included:

Small Market Television: Hard News – WHO 13 in Des Moines, Iowa, was honored for “Robin’s Voice,” a powerful story of Robin Leaper, who lost her ability to speak due to ALS after being diagnosed in 2023. Through advances in AI technology, Ms. Leaper regained her ability to communicate using a computer-generated version of her own voice, helping restore a vital sense of connection and dignity. https://youtu.be/cuMHu7pIkXo?si=Eho9UXwtB-2LSl4x

“We are grateful to the Radio Television Digital News Association for recognizing the outstanding work of our newsrooms,” said Andrew Alford, President of Nexstar’s broadcasting division. “Nexstar remains committed to investing in strong local journalism and providing the free, trusted news and information that viewers across America rely on and deserve. We are steadfast in our support of local news and the vital role it plays in informing, connecting, and strengthening communities. Thank you again to RTDNA for the national Edward R. Murrow Awards.”

In addition to the national honors won today, Nexstar news operations at 20 of its owned and operated television stations earned a total of 34 regional Edward R. Murrow Awards earlier this year.

The RTDNA has been recognizing outstanding achievements in electronic journalism with the Edward R. Murrow Awards since 1971.

About Nexstar Media Group, Inc.

Nexstar Media Group, Inc. (NASDAQ: NXST) is a leading diversified media company that produces and distributes engaging local and national news, sports and entertainment content across its television and digital platforms. For more information, please visit nexstar.tv.

MEDIA CONTACT:

Gary Weitman

EVP and Chief Communications Officer

Nexstar Media Group, Inc.

972/373-8800 (office) or [email protected]

INVESTOR CONTACT:

Joe Jaffoni or Jennifer Neuman

JCIR

212/835-8500 or [email protected]

KEYWORDS: Texas Iowa United States North America

INDUSTRY KEYWORDS: Technology Entertainment Marketing Advertising Online Communications Audio/Video Media TV and Radio

MEDIA:

Logo
Logo
Posted on

Gibraltar to Attend Seaport Research Partners 2026 Annual Summer Investor Conference

Gibraltar to Attend Seaport Research Partners 2026 Annual Summer Investor Conference

BUFFALO, N.Y.–(BUSINESS WIRE)–
Gibraltar Industries, Inc. (Nasdaq: ROCK), a leading manufacturer and provider of products and services for the residential, agtech and infrastructure markets, today announced that Chairman and Chief Executive Officer Bill Bosway and Chief Financial Officer Joe Lovechio are scheduled to participate at the Seaport Research Partners Annual Summer Investor Conference on Tuesday, August 18, 2026, holding meetings with investors that day.

About Gibraltar

Gibraltar is a leading manufacturer and provider of products and services for the residential, agtech, and infrastructure markets. Gibraltar’s mission, to make life better for people and the planet, is fueled by advancing the disciplines of engineering, science, and technology. Gibraltar is innovating to reshape critical markets in comfortable living and productive growing throughout North America. For more please visit www.gibraltar1.com.

Alliance Advisors IR

Jody Burfening/Carolyn Capaccio

(212) 838-3777

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Technology Utilities Residential Building & Real Estate Agritech Energy Construction & Property

MEDIA:

Logo
Logo
Posted on

UWMC INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of UWM Holdings Corporation Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm 

ATLANTA, Aug. 14, 2026 (GLOBE NEWSWIRE) — A shareholder class action lawsuit has been filed against UWM Holdings Corporation (“UWM”) (NYSE: UWMC). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (1) UWM had deviated from its traditional strategy of not hedging its mortgage servicing rights to take a major hedge position; (2) UWM over-hedged itself in anticipation of the Two Harbors transaction; and (3) UWM’s purported efforts to balance its risk in fact created an excess hedging risk.

If you purchased UWM shares between March 9, 2026 and August 5, 2026, and experienced a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/uwm/ for more information. 

The deadline to ask the court to be appointed lead plaintiff in the case is October 12, 2026. 

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.  

CONTACT:
Corey D. Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]